CoChat

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

Bruckert, Eric, Hayem, Gilles, Dejager, Sylvie, Yau, Caroline, Bégaud, Bernard · 2005 · Cardiovascular Drugs and Therapy

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Abstract

Objectives To characterize the risk factors, rate of occurrence, onset, nature and impact of mild to moderate muscular symptoms with high-dosage HMG-CoA reductase inhibitor (statin) therapy in general practice.Methods The Prédiction du Risque Musculaire en Observationnel (Prediction of Muscular Risk in Observational conditions, PRIMO) survey was an observational study of muscular symptoms in an unselected population of 7924 hyperlipidemic patients receiving high-dosage statin therapy in a usual care, outpatient setting in France. Information on patient demographics, treatment history and muscular symptoms was obtained by questionnaires.Results Multivariate analysis revealed the strongest predictors for muscular symptoms to be a personal history of muscle pain during lipid-lowering therapy (odds ratio, OR, 10.12, 95% CI 8.23-12.45; P < 0.0001), unexplained cramps (OR 4.14; 95% CI 3.46-4.95; P < 0.0001) and a history of creatine kinase (CK) elevation (OR 2.04; 95% CI 1.55-2.68; P < 0.0001). Overall, muscular symptoms were reported by 832 patients (10.5%), with a median time of onset of 1 month following initiation of statin therapy. Muscular pain prevented even moderate exertion during everyday activities in 315 patients (38%), while 31 (4%) were confined to bed or unable to work. Fluvastatin XL was associated with the lowest rate of muscular symptoms (5.1%) among individual statins.Conclusion PRIMO demonstrated that mild to moderate muscular symptoms with high-dosage statin therapy may be more common and exert a greater impact on everyday lives than previously thought. Knowledge of the risk factors for muscular symptoms will allow identification and improved management of high-risk patients. The risk of muscular symptoms with fluvastatin XL treatment may be lower than with high dosages of other statins.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10557-005-5686-z

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Research works printed but not linked: 2

  1. Adverse Drug Reactions Advisory Committee (ADRAC). Risk factors for myopathy and rhabdomyolysis with the statins. Aust Adv Drug Reactions Bull 2004;23(1):1–2.
  2. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35(9):1096–1107. · doi:10.1345/aph.10228 · Paper page

Cited by

See all 1,226

Metadata

Authors
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B.
Affiliations
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Novartis (France) (FR)
  • Université Bordeaux Segalen (FR)
Venue
Cardiovascular Drugs and Therapy
Published
2005-12
Volume
19
Issue
6
Pages
403-414
ISSN
  • 0920-3206 (ISSN-L)
  • 1573-7241
OpenAlex
W2010033213
Cited by
1,226
References
37
Citations by year
2026: 8 · 2025: 25 · 2024: 49 · 2023: 52 · 2022: 51 · 2021: 53 · 2020: 80 · 2019: 80 · 2018: 87 · 2017: 84 · 2016: 115 · 2015: 99 · 2014: 110 · 2013: 77 · 2012: 66
FWCI
16.68
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cardiovascular Drugs and Therapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novartis Pharma
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
statin-induced myopathy, statins, hyperlipidemia, risk factors, myalgia, creatine kinase elevation, statin adverse effects
MeSH terms
Aged, Alcohol Drinking, Dose-Response Relationship, Drug, Female, France, Humans, Hyperlipidemias, Male, Middle Aged, Musculoskeletal Diseases, Outpatients, Pain, Predictive Value of Tests, Surveys and Questionnaires, Risk Factors, Smoking, Multivariate Analysis, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. https://app.cochat.ai/papers/10.1007/s10557-005-5686-z
The paper
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005). Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-005-5686-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.